Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

New era of early cancer detection blood tests on the horizon

Hyperthermic intraperitoneal chemo for locally advanced colon cancer

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data

How air pollution may trigger lung cancer in never-smokers